

Raban V Jeger

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7798798/publications.pdf>

Version: 2024-02-01

151
papers

18,466
citations

101543

36
h-index

12946

131
g-index

162
all docs

162
docs citations

162
times ranked

16787
citing authors

#	ARTICLE	IF	CITATIONS
1	Safety and Efficacy of Drug-Coated Balloons Versus Drug-Eluting Stents in Acute Coronary Syndromes: A Prespecified Analysis of BASKET-SMALL 2. <i>Circulation: Cardiovascular Interventions</i> , 2022, 15, CIRCINTERVENTIONS121011325.	3.9	15
2	Soluble urokinase plasminogen activator receptor and functionally relevant coronary artery disease: a prospective cohort study. <i>Biomarkers</i> , 2022, 27, 278-285.	1.9	2
3	Drug-coated balloons for small coronary artery disease in patients with chronic kidney disease: a pre-specified analysis of the BASKET-SMALL 2 trial. <i>Clinical Research in Cardiology</i> , 2022, 111, 806-815.	3.3	8
4	Drug-Coated Balloon for Small Coronary Artery Disease in Patients With and Without High-Bleeding Risk in the BASKET-SMALL 2 Trial. <i>Circulation: Cardiovascular Interventions</i> , 2022, 15, 101161CIRCINTERVENTIONS121011569.	3.9	17
5	First-in-man concomitant mitral valve replacement and coronary artery bypass grafting using a single minimally invasive access. <i>European Journal of Cardio-thoracic Surgery</i> , 2022, 62, .	1.4	3
6	Causes of death after treatment of small coronary artery disease with paclitaxel-coated balloons. <i>Clinical Research in Cardiology</i> , 2021, 110, 307-311.	3.3	6
7	Four-year mortality in women and men after transfemoral transcatheter aortic valve implantation using the SAPIEN 3. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 97, 876-884.	1.7	10
8	Transcatheter Aortic Valve Replacement With the LOTUS Edge System. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 172-181.	2.9	6
9	Infective endocarditis: prevention and antibiotic prophylaxis. <i>Swiss Medical Weekly</i> , 2021, 151, w20473.	1.6	2
10	Effect of COVID-19 on acute treatment of ST-segment elevation and Non-ST-segment elevation acute coronary syndrome in northwestern Switzerland. <i>IJC Heart and Vasculature</i> , 2021, 32, 100686.	1.1	7
11	A review of recommendations for infective endocarditis prevention in patients undergoing transcatheter aortic valve implantation. <i>EuroIntervention</i> , 2021, 16, 1135-1140.	3.2	21
12	Incidence and outcomes of perioperative myocardial infarction/injury diagnosed by high-sensitivity cardiac troponin I. <i>Clinical Research in Cardiology</i> , 2021, 110, 1450-1463.	3.3	18
13	Coronary and structural heart interventions in Switzerland 2019. <i>Swiss Medical Weekly</i> , 2021, 151, w20495.	1.6	3
14	Age-Related Outcomes After Transcatheter Aortic Valve Replacement. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 952-960.	2.9	28
15	Impact of anemia on short-term outcomes after TAVR : A subgroup analysis from the BRAVO 3 randomized trial. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 98, E870-E880.	1.7	2
16	Non-invasive predictors for infranodal conduction delay in patients with left bundle branch block after TAVR. <i>Clinical Research in Cardiology</i> , 2021, 110, 1967-1976.	3.3	0
17	Impact of Diabetes on Outcome With Drug-Coated Balloons Versus Drug-Eluting Stents. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 1789-1798.	2.9	22
18	Drug-coated Balloons for Small Coronary Disease – A Literature Review. <i>Current Cardiology Reports</i> , 2021, 23, 173.	2.9	4

#	ARTICLE	IF	CITATIONS
19	Reduced Leaflet Motion after Transcatheter Aortic-Valve Replacement. New England Journal of Medicine, 2020, 382, 130-139.	27.0	194
20	Drug-coated balloons in cardiovascular disease: benefits, challenges, and clinical applications. Expert Opinion on Drug Delivery, 2020, 17, 201-211.	5.0	20
21	Clinical outcomes after TAVR with heparin or bivalirudin as periprocedural anticoagulation in patients with and without peripheral arterial disease: Results from the BRAVO-3 randomized trial. Catheterization and Cardiovascular Interventions, 2020, 96, E377-E386.	1.7	5
22	Long-term efficacy and safety of drug-coated balloons versus drug-eluting stents for small coronary artery disease (BASKET-SMALL 2): 3-year follow-up of a randomised, non-inferiority trial. Lancet, The, 2020, 396, 1504-1510.	13.7	96
23	Long-Term Results After Drug-Eluting Versus Bare-Metal Stent Implantation in Saphenous Vein Grafts: Randomized Controlled Trial. Journal of the American Heart Association, 2020, 9, e017434.	3.7	7
24	Using High-Sensitivity Cardiac Troponin for the Exclusion of Inducible Myocardial Ischemia in Symptomatic Patients. Annals of Internal Medicine, 2020, 172, 175.	3.9	14
25	Heavy Drinking Habits Are Associated with Worse In-Hospital Outcomes in Patients with Acute Coronary Syndrome: An Insight from the AMIS Plus Registry. Cardiology, 2020, 145, 757-765.	1.4	2
26	Two cases of successful treatment of acute right heart failure with Impella RP®. ESC Heart Failure, 2020, 7, 1982-1986.	3.1	2
27	Drug-Coated Balloons for Coronary Artery Disease. JACC: Cardiovascular Interventions, 2020, 13, 1391-1402.	2.9	218
28	Infective Endocarditis After Transcatheter Aortic Valve Replacement. Journal of the American College of Cardiology, 2020, 75, 3020-3030.	2.8	60
29	A Randomized Trial of Recombinant Human C1-Esterase-Inhibitor in the Prevention of Contrast-Induced Kidney Injury. JACC: Cardiovascular Interventions, 2020, 13, 833-842.	2.9	10
30	Sex-Specific Management in Patients With Acute Myocardial Infarction and Cardiogenic Shock. Circulation: Cardiovascular Interventions, 2020, 13, e008537.	3.9	35
31	Electrophysiology Testing to Stratify Patients With Left Bundle Branch Block After Transcatheter Aortic Valve Implantation. Journal of the American Heart Association, 2020, 9, e014446.	3.7	23
32	Survival After Coronary Revascularization With Paclitaxel-Coated Balloons. Journal of the American College of Cardiology, 2020, 75, 1017-1028.	2.8	70
33	Drug-coated balloon versus drug-eluting stent in small coronary artery lesions: angiographic analysis from the BASKET-SMALL 2 trial. Clinical Research in Cardiology, 2020, 109, 1114-1124.	3.3	18
34	Impact of mitral regurgitation aetiology on MitraClip outcomes: the MitraSwiss registry. EuroIntervention, 2020, 16, e112-e120.	3.2	14
35	Coronary and structural heart interventions in Switzerland 2018. Swiss Medical Weekly, 2020, 150, w20200.	1.6	1
36	Clinical Outcomes of the Portico Transcatheter Aortic Valve Delivered via Alternative Access: 30-Day and 1-Year Results of the Portico ALT Study. Journal of Invasive Cardiology, 2020, 32, 405-411.	0.4	0

#	ARTICLE	IF	CITATIONS
37	2018 ESC/EACTS Guidelines on myocardial revascularization. European Heart Journal, 2019, 40, 87-165.	2.2	4,537
38	2018 ESC/EACTS Guidelines on myocardial revascularization. European Journal of Cardio-thoracic Surgery, 2019, 55, 4-90.	1.4	402
39	Impact of Diabetes Mellitus in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents. Circulation: Cardiovascular Interventions, 2019, 12, e007734.	3.9	6
40	Early Diagnosis of Myocardial Infarction in Patients With a History of Coronary Artery Bypass Grafting. Journal of the American College of Cardiology, 2019, 74, 587-589.	2.8	7
41	Do ultrathin strut bare-metal stents with passive coating improve efficacy in large coronary arteries? Insights from the randomized, multicenter BASKET-PROVE trials. BMC Cardiovascular Disorders, 2019, 19, 226.	1.7	1
42	TCT-803 Clinical Outcomes After TAVR in Patients With and Without Peripheral Arterial Disease: Results From the BRAVO-3 Randomized Trial. Journal of the American College of Cardiology, 2019, 74, B787.	2.8	0
43	Impact of diabetes mellitus on short term vascular complications after TAVR: Results from the BRAVO-3 randomized trial. International Journal of Cardiology, 2019, 297, 22-29.	1.7	10
44	Local Versus General Anesthesia for Transcatheter Aortic Valve Replacement. JACC: Cardiovascular Interventions, 2019, 12, 1874-1876.	2.9	3
45	The hospital results and 1-year outcomes of transcatheter aortic valve-in-valve procedures and transcatheter aortic valve implantations in the native valves: the results from the Swiss-TAVI Registry. European Journal of Cardio-thoracic Surgery, 2019, 56, 55-63.	1.4	32
46	Competing risks of major bleeding and thrombotic events with prasugrel-based dual antiplatelet therapy after stent implantation - An observational analysis from BASKET-PROVE II. PLoS ONE, 2019, 14, e0210821.	2.5	5
47	Impact of percutaneous closure device type on vascular and bleeding complications after TAVR: A post hoc analysis from the BRAVO-3 randomized trial. Catheterization and Cardiovascular Interventions, 2019, 93, 1374-1381.	1.7	35
48	Drug-coated balloons: room for development of BASKET-SMALL 2 – Authors' reply. Lancet, The, 2019, 393, 1934-1935.	13.7	0
49	Prevalence and determinants of exercise-induced left ventricular dysfunction in patients with coronary artery disease. European Journal of Clinical Investigation, 2019, 49, e13112.	3.4	0
50	Perioperative major adverse cardiac events in urgent femoral artery repair after coronary stenting are less common than previously reported. Journal of Vascular Surgery, 2019, 70, 216-223.	1.1	0
51	Twenty-Year Trends in the Incidence and Outcome of Cardiogenic Shock in AMIS Plus Registry. Circulation: Cardiovascular Interventions, 2019, 12, e007293.	3.9	72
52	Drug-eluting stents in large coronary vessels improve both safety and efficacy compared with bare-metal stents in women: a pooled analysis of the BASKET-PROVE I and II trials. Open Heart, 2019, 6, e000986.	2.3	4
53	Clinical utility of circulating interleukin-6 concentrations in the detection of functionally relevant coronary artery disease. International Journal of Cardiology, 2019, 275, 20-25.	1.7	10
54	Temporal trends in adoption and outcomes of transcatheter aortic valve implantation: a SwissTAVI Registry analysis. European Heart Journal Quality of Care & Clinical Outcomes, 2019, 5, 242-251.	4.0	59

#	ARTICLE	IF	CITATIONS
55	New-onset or Pre-existing Atrial Fibrillation in Acute Coronary Syndromes: Two Distinct Phenomena With a Similar Prognosis. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2019, 72, 383-391.	0.6	10
56	Drug-coated Balloons for Small Coronary Vessel Interventions: A Literature Review. <i>Interventional Cardiology Review</i> , 2019, 14, 131-136.	1.6	14
57	Effects of Body Mass Index on Clinical Outcomes in Female Patients Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 68-76.	2.9	28
58	Effect of Increasing Stent Length on 3-Year Clinical Outcomes in Women Undergoing Percutaneous Coronary Intervention With New-Generation Drug-Eluting Stents. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 53-65.	2.9	22
59	Drug-coated balloons for de novo lesions in small coronary arteries: rationale and design of BASKET-SMALL 2. <i>Clinical Cardiology</i> , 2018, 41, 569-575.	1.8	13
60	Second generation drug-eluting stents versus bare-metal stents for percutaneous coronary intervention of the proximal left anterior descending artery: An analysis of the BASKET-PROVE I and II trials. <i>Catheterization and Cardiovascular Interventions</i> , 2018, 91, 867-873.	1.7	4
61	2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. <i>European Heart Journal</i> , 2018, 39, 119-177.	2.2	7,100
62	Supra-annular sizing for transcatheter valve implantation in bicuspid aortic stenosis. <i>Postepy W Kardiologii Interwencyjnej</i> , 2018, 14, 187-190.	0.2	5
63	Stents in saphenous vein grafts. <i>Lancet, The</i> , 2018, 391, 1967-1968.	13.7	5
64	Direct Comparison of Cardiac Troponin T and I Using a Uniform and a Sex-Specific Approach in the Detection of Functionally Relevant Coronary Artery Disease. <i>Clinical Chemistry</i> , 2018, 64, 1596-1606.	3.2	19
65	Drug-coated balloons for small coronary artery disease (BASKET-SMALL 2): an open-label randomised non-inferiority trial. <i>Lancet, The</i> , 2018, 392, 849-856.	13.7	263
66	Long-term outcomes in patients with rheumatologic disorders undergoing percutaneous coronary intervention: a BASel Stent Kosten-Effektivitäts Trial-PROspective Validation Examination (BASKET-PROVE) sub-study. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2017, 6, 778-786.	1.0	10
67	Impact of pre-existing or new-onset atrial fibrillation on 30-day clinical outcomes following transcatheter aortic valve replacement: Results from the BRAVO 3 randomized trial. <i>Catheterization and Cardiovascular Interventions</i> , 2017, 90, 1027-1037.	1.7	8
68	Heart failure in patients admitted for acute coronary syndromes: A report from a large national registry. <i>Clinical Cardiology</i> , 2017, 40, 907-913.	1.8	13
69	Predictors and prognostic impact of silent coronary artery disease in asymptomatic high-risk patients with diabetes mellitus. <i>International Journal of Cardiology</i> , 2017, 244, 37-42.	1.7	32
70	Predicting Mortality After Transcatheter Aortic Valve Replacement. <i>Circulation: Cardiovascular Interventions</i> , 2017, 10, .	3.9	32
71	Long-term Safety and Efficacy of New-Generation Drug-Eluting Stents in Women With Acute Myocardial Infarction. <i>JAMA Cardiology</i> , 2017, 2, 855.	6.1	25
72	Frequency of Cardiac Death and Stent Thrombosis in Patients With Chronic Obstructive Pulmonary Disease Undergoing Percutaneous Coronary Intervention (from the BASKET-PROVE I and II Trials). <i>American Journal of Cardiology</i> , 2017, 119, 14-19.	1.6	12

#	ARTICLE	IF	CITATIONS
73	The Neurocardiogenic Spectrum in Subarachnoid Hemorrhage: A Case Report and Review of the Literature. <i>Clinical Practice and Cases in Emergency Medicine</i> , 2017, 1, 16-21.	0.3	4
74	Comparison of procedural and clinical outcomes with Evolut R versus Medtronic CoreValve: a Swiss TAVI registry analysis. <i>EuroIntervention</i> , 2017, 12, e2170-e2176.	3.2	51
75	First-generation paclitaxel- vs. second-generation zotarolimus-eluting stents in small coronary arteries: the BASKET-SMALL Pilot Study. <i>Postępy W Kardiologii Interwencyjnej</i> , 2016, 4, 314-320.	0.2	6
76	TCT-312 Increased Cardiac Death and Stent Thrombosis in Chronic Obstructive Pulmonary Disease Patients Undergoing Percutaneous Coronary Intervention. An analysis of the BASKET-PROVE I and II trials. <i>Journal of the American College of Cardiology</i> , 2016, 68, B129.	2.8	4
77	TCT-475 Effect of Stent Diameter in Women Undergoing Percutaneous Coronary Intervention with Early- and New-Generation Drug-Eluting Stents: From the Women in Innovation and Drug-Eluting Stents (WIN-DES) Collaboration. <i>Journal of the American College of Cardiology</i> , 2016, 68, B191.	2.8	0
78	Repositionable Versus Balloon-Expandable Devices for Transcatheter Aortic Valve Implantation in Patients With Aortic Stenosis. <i>Journal of the American Heart Association</i> , 2016, 5, .	3.7	25
79	Safety and Efficacy of New-Generation Drug-Eluting Stents in Women Undergoing Complex Percutaneous Coronary Artery Revascularization. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 674-684.	2.9	51
80	Correlates and Impact of Coronary Artery Calcifications in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 1890-1901.	2.9	32
81	Incidence and Predictors of Cardiomyocyte Injury in Elective Coronary Angiography. <i>American Journal of Medicine</i> , 2016, 129, 537.e1-537.e8.	1.5	4
82	Effect of Chronic Kidney Disease in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 28-38.	2.9	31
83	Safety and Efficacy of New-Generation Drug-Eluting Stents in Women at High Risk for Atherothrombosis. <i>Circulation: Cardiovascular Interventions</i> , 2016, 9, e002995.	3.9	12
84	Letter by Jeger and Pfisterer Regarding Article, "Prasugrel Plus Aspirin Beyond 12 Months Is Associated With Improved Outcomes After TAXUS Libert [®] Paclitaxel-Eluting Coronary Stent Placement". <i>Circulation</i> , 2015, 132, e165.	1.6	0
85	Duration of Dual Antiplatelet Therapy after Drug-Eluting Stents. <i>New England Journal of Medicine</i> , 2015, 372, 1371-1374.	27.0	18
86	Long-Term Efficacy and Safety of Biodegradable-Polymer Biolimus-Eluting Stents. <i>Circulation</i> , 2015, 131, 74-81.	1.6	87
87	Bivalirudin Versus Heparin Anticoagulation in Transcatheter Aortic Valve Replacement. <i>Journal of the American College of Cardiology</i> , 2015, 66, 2860-2868.	2.8	116
88	Procedural Results and Clinical Outcomes of Transcatheter Aortic Valve Implantation in Switzerland. <i>Circulation: Cardiovascular Interventions</i> , 2015, 8, .	3.9	64
89	Impact of Clinical Presentation (Stable Angina Pectoris vs Unstable Angina Pectoris or T ₁ ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 11 Outcomes in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents. <i>American Journal of Cardiology</i> , 2015, 116, 845-852.	1.6	32
90	Improved outcomes of elderly patients treated with drug-eluting versus bare metal stents in large coronary arteries: Results from the BASel Stent Kosten-Effektivitäts Trial PROspective Validation Examination randomized trial. <i>American Heart Journal</i> , 2015, 170, 787-795.e1.	2.7	11

#	ARTICLE	IF	CITATIONS
91	Abstract 16776: Drug-eluting Stents in Large Coronary Vessels Improve Both Safety and Efficacy in Women Compared to Bare-metal Stents. <i>Circulation</i> , 2015, 132, .	1.6	0
92	Abstract 16775: Efficacy and Safety of a Thinner-strut Silicon Carbide-coated Cobalt Chromium Bare-metal Stent Compared to a Thin-strut Uncoated Cobalt Chromium Bare-metal Stent in Large Vessel Stenting: Insights From Two Prospective Randomised All-comers Trials. <i>Circulation</i> , 2015, 132, .	1.6	0
93	Prolonged dual antiplatelet therapy in renal failure: a challenging trade-off. <i>Journal of Thoracic Disease</i> , 2015, 7, E625-8.	1.4	1
94	Single-Center Experience and Short-term Outcome with the JenaValve: A Second-Generation Transapical Transcatheter Aortic Valve Implantation Device. <i>Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery</i> , 2014, 9, 368-374.	0.9	5
95	Pacemaker Implantation and Need for Ventricular Pacing during Follow-up after Transcatheter Aortic Valve Implantation. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2014, 37, 1592-1601.	1.2	37
96	Prognostic Value of "Routine" Cardiac Stress Imaging 5 Years After Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2014, 7, 615-621.	2.9	25
97	Tradeoff between bleeding and stent thrombosis in different dual antiplatelet therapy regimes: Importance of case fatality rates and effective treatment durations. <i>American Heart Journal</i> , 2014, 168, 698-705.e2.	2.7	9
98	Percutaneous Mitral Valve Edge-to-Edge Repair. <i>Journal of the American College of Cardiology</i> , 2014, 64, 875-884.	2.8	398
99	Progression to Overt or Silent CAD in Asymptomatic Patients With Diabetes Mellitus at High Coronary Risk. <i>JACC: Cardiovascular Imaging</i> , 2014, 7, 1001-1010.	5.3	70
100	Acute multivessel revascularization improves 1-year outcome in ST-elevation myocardial infarction. <i>International Journal of Cardiology</i> , 2014, 172, 76-81.	1.7	34
101	Short-term clinical outcomes among patients undergoing transcatheter aortic valve implantation in Switzerland: the Swiss TAVI registry. <i>EuroIntervention</i> , 2014, 10, 982-989.	3.2	57
102	First-in-man Portico® transcatheter aortic valve-in-valve implantation in a degenerated 19 mm Mitroflow® aortic pericardial heart valve. <i>EuroIntervention</i> , 2014, 9, 1368-1368.	3.2	7
103	Single-Center Experience and Short-term Outcome with the JenaValve: A Second-Generation Transapical Transcatheter Aortic Valve Implantation Device. <i>Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery</i> , 2014, 9, 368-374.	0.9	1
104	Interventional treatment for structural heart disease: Who is deciding, and can we afford it?. <i>Swiss Medical Weekly</i> , 2014, 144, w14046.	1.6	1
105	Drug-coated balloons for treatment of coronary artery disease: updated recommendations from a consensus group. <i>Clinical Research in Cardiology</i> , 2013, 102, 785-797.	3.3	157
106	Long-term benefits and risks of drug-eluting compared to bare-metal stents in patients with versus without chronic kidney disease. <i>International Journal of Cardiology</i> , 2013, 168, 2381-2388.	1.7	15
107	Safety and efficacy of drug-eluting stents in women: a patient-level pooled analysis of randomised trials. <i>Lancet, The</i> , 2013, 382, 1879-1888.	13.7	127
108	Transcatheter Aortic Valve Replacement in Europe. <i>Journal of the American College of Cardiology</i> , 2013, 62, 210-219.	2.8	199

#	ARTICLE	IF	CITATIONS
109	Long-term safety of drug-eluting stents. Expert Review of Cardiovascular Therapy, 2013, 11, 1359-1378.	1.5	5
110	Mens sana in corpore sano revisited. European Heart Journal, 2013, 34, 2580-2581.	2.2	5
111	By a Hair's Breadth. Circulation, 2013, 128, 84-85.	1.6	0
112	Predictors for efficacy of percutaneous mitral valve repair using the MitraClip system: the results of the MitraSwiss registry. Heart, 2013, 99, 1034-1040.	2.9	126
113	Stent Thrombosis after Coronary Stent Implantation: A Protective Effect of High-Dose Statin Therapy?. Cardiology, 2013, 126, 115-121.	1.4	5
114	Multivessel versus culprit vessel percutaneous coronary intervention in ST-elevation myocardial infarction: is more worse?. EuroIntervention, 2013, 9, 909-915.	3.2	26
115	No One-Size-Fits-All. Circulation, 2012, 125, 471-473.	1.6	8
116	Newest-generation drug-eluting and bare-metal stents combined with prasugrel-based antiplatelet therapy in large coronary arteries: The BASel Stent Kosten Effektivitäts Trial PROspective Validation Examination part II (BASKET-PROVE II) trial design. American Heart Journal, 2012, 163, 136-141.e1.	2.7	15
117	Coronary Artery Disease Progression Late After Successful Stent Implantation. Journal of the American College of Cardiology, 2012, 59, 793-799.	2.8	58
118	Heart Failure in Post-MI Patients With Persistent IRA Occlusion: Prevalence, Risk Factors, and the Long-Term Effect of PCI in the Occluded Artery Trial (OAT). Journal of Cardiac Failure, 2012, 18, 813-821.	1.7	3
119	Combined clopidogrel and proton pump inhibitor therapy is associated with higher cardiovascular event rates after percutaneous coronary intervention: a report from the BASKET trial. Journal of Internal Medicine, 2012, 271, 257-263.	6.0	45
120	Statins: have we found the Holy Grail?. Swiss Medical Weekly, 2012, 142, w13515.	1.6	12
121	Limited Usefulness of the Modified Academic Research Consortium Stent Thrombosis Definition for Clinical Trials. JACC: Cardiovascular Interventions, 2011, 4, 1151.	2.9	2
122	Early revascularization is beneficial across all ages and a wide spectrum of cardiogenic shock severity: A pooled analysis of trials. Acute Cardiac Care, 2011, 13, 14-20.	0.2	32
123	The Angio-Seal, a femoral closure device allows immediate ambulation after coronary angiography and percutaneous coronary intervention. EuroIntervention, 2011, 7, 234-241.	3.2	25
124	Drug-eluting coronary stents in clinical practice: lessons from the BASel Stent Kosten-Effektivitäts Trials (BASKET). Swiss Medical Weekly, 2011, 141, w13263.	1.6	5
125	Drug-Eluting versus Bare-Metal Stents in Large Coronary Arteries. New England Journal of Medicine, 2010, 363, 2310-2319.	27.0	243
126	Low Rate of Heart Failure Hospitalization after Myocardial Infarction in the Occluded Artery Trial (OAT). Journal of Cardiac Failure, 2010, 16, S83.	1.7	0

#	ARTICLE	IF	CITATIONS
127	Drug-eluting stents for saphenous vein graft lesions: useful or harmful?. <i>EuroIntervention</i> , 2010, 5, 647-648.	3.2	0
128	Drug-Eluting Stents Compared with Bare Metal Stents Improve Late Outcome after Saphenous Vein Graft but Not after Large Native Vessel Interventions. <i>Cardiology</i> , 2009, 112, 49-55.	1.4	57
129	Ischaemic mitral regurgitation. <i>European Heart Journal</i> , 2009, 30, 1573-1573.	2.2	0
130	Drug-eluting stents and glycoprotein IIb/IIIa inhibitors in vessels at low anatomic risk: A retrospective analysis of previously published data from the Basel Stent Kosten Effektivitäts Trial. <i>Clinical Therapeutics</i> , 2009, 31, 2886-2893.	2.5	4
131	Early and late increased bleeding rates after angioplasty and stenting due to combined antiplatelet and anticoagulant therapy. <i>EuroIntervention</i> , 2009, 5, 425-431.	3.2	25
132	A Comparison of the Blood Pressure Changes of Lumiracoxib With Those of Ibuprofen and Naproxen. <i>Journal of Clinical Hypertension</i> , 2008, 10, 592-602.	2.0	8
133	Outpatient Rehabilitation in Patients With Coronary Artery and Peripheral Arterial Occlusive Disease. <i>Archives of Physical Medicine and Rehabilitation</i> , 2008, 89, 618-621.	0.9	27
134	Long-term benefit-risk balance of drug-eluting vs. bare-metal stents in daily practice: does stent diameter matter? Three-year follow-up of BASKET. <i>European Heart Journal</i> , 2008, 30, 16-24.	2.2	99
135	Ten-Year Trends in the Incidence and Treatment of Cardiogenic Shock. <i>Annals of Internal Medicine</i> , 2008, 149, 618.	3.9	309
136	Hemodynamic Parameters Are Prognostically Important in Cardiogenic Shock But Similar Following Early Revascularization or Initial Medical Stabilization. <i>Chest</i> , 2007, 132, 1794-1803.	0.8	33
137	Oral Hypoglycemics: Increased Postoperative Mortality in Coronary Risk Patients. <i>Cardiology</i> , 2007, 107, 296-301.	1.4	5
138	Causes of death and re-hospitalization in cardiogenic shock. <i>Acute Cardiac Care</i> , 2007, 9, 25-33.	0.2	36
139	Cost-effectiveness of drug-eluting stents in patients at high or low risk of major cardiac events in the Basel Stent Kosten Effektivitäts Trial (BASKET): an 18-month analysis. <i>Lancet, The</i> , 2007, 370, 1552-1559.	13.7	91
140	Benefit of outpatient cardiac rehabilitation in under-represented patient subgroups. <i>Acta Dermato-Venereologica</i> , 2007, 39, 246-251.	1.3	18
141	Late Clinical Events After Clopidogrel Discontinuation May Limit the Benefit of Drug-Eluting Stents. <i>Journal of the American College of Cardiology</i> , 2006, 48, 2584-2591.	2.8	1,242
142	Interhospital transfer for early revascularization in patients with ST-elevation myocardial infarction complicated by cardiogenic shock—a report from the SHould we revascularize Occluded Coronaries for cardiogenic shock? (SHOCK) trial and registry. <i>American Heart Journal</i> , 2006, 152, 686-692.	2.7	30
143	Long-term prognostic value of the preoperative 12-lead electrocardiogram before major noncardiac surgery in coronary artery disease. <i>American Heart Journal</i> , 2006, 151, 508-513.	2.7	68
144	Selection bias of elderly patients with chronic angina referred for catheterization. <i>International Journal of Cardiology</i> , 2006, 110, 80-85.	1.7	7

#	ARTICLE	IF	CITATIONS
145	Randomized, Double-Blind Comparison of Acute β 1-Blockade With 50 mg Metoprolol Tartrate vs 25 mg Carvedilol in Normal Subjects. Congestive Heart Failure, 2006, 12, 254-257.	2.0	6
146	Emergency revascularization in patients with cardiogenic shock on admission: a report from the SHOCK trial and registry. European Heart Journal, 2006, 27, 664-670.	2.2	87
147	Influence of Revascularization on Long-Term Outcome in Patients \geq 75 Years of Age With Diabetes Mellitus and Angina Pectoris. American Journal of Cardiology, 2005, 96, 193-198.	1.6	8
148	Lumiracoxib, a highly selective COX-2 inhibitor. Expert Review of Clinical Immunology, 2005, 1, 37-45.	3.0	6
149	Prognostic Value of Stress Testing in Patients Over 75 Years of Age With Chronic Angina. Chest, 2004, 125, 1124-1131.	0.8	23
150	Heart rate variability and cardiac troponin I are incremental and independent predictors of one-year all-cause mortality after major noncardiac surgery in patients at risk of coronary artery disease. Journal of the American College of Cardiology, 2003, 42, 1767-1776.	2.8	106
151	Long-term outcome of patients with silent versus symptomatic ischemia six months after percutaneous coronary intervention and stenting. Journal of the American College of Cardiology, 2003, 42, 33-40.	2.8	100